Gut bacteria and intermittent fasting in an MS model

associate-professor-laurence-macia

Associate Professor Laurence Macia

The University of Sydney, NSW

| Better treatments | Social And Applied Research | Incubator | 2020 | Investigator Led Research |
SUPPORT PROJECTS WITH THIS RESEARCH FOCUS

Summary

MS is characterised by immune cells attacking and destroying myelin, the insulating component of nerve cells in the central nervous system. MS is more common in western countries compared to Asia and Africa and this is due to genetic differences and environmental factors, such as diet. One way diet may be playing a role is by shaping the bacteria in our guts. There is now strong evidence that gut bacteria play a critical role in regulating immune responses in MS and other diseases. Butyrate is a molecule produced by gut bacteria and the amount produced is dependent on a person’s diet. Butyrate changes the way immune cells function by sticking to a protein on their surface called GPR109A.

Associate Professor Laurence Macia and her team have shown that intermittent fasting is very effective in improving symptoms in a laboratory model of MS. Preliminary results have also shown that levels of butyrate increase with intermittent fasting. Associate Professor Macia and her team plan to study whether the beneficial effects they see in their models of MS are due to butyrate and GPR109A interacting together.

Project Outcomes

The study found that the absence of GPR109A leads to a delayed onset and less severe disease in a laboratory model of MS. This outcome was the opposite of what the study investigators expected to see. This suggests that GPR109A may be a new target to control inflammation in MS in the future. The researchers also found that the background diet (either normal diet or intermittent fasting) did not have any impact; it was the lack of GPR109A that made the difference. The absence of butyrate also resulted in reduced disease severity. As with all laboratory research, it must be remembered that results at this level do not directly transfer to humans living with MS at this point. The context of the laboratory research is to provide insights for further exploration.

In the next year, the study team hopes to conduct further research to better understand the mechanisms underlying these new discoveries so that their importance and relationship to MS can be established. Associate Professor Macia and her study team plan to explore dietary interventions and how macronutrient compositions (carbohydrate, fat and protein) could affect MS.

Updated: 6 April 2021

Updated: 21 January, 2020

Stages of the research process

Fundamental laboratory
Research

Laboratory research that investigates scientific theories behind the possible causes, disease progression, ways to diagnose and better treat MS.

Lab to clinic timeline: 10+ years
Translational
Research

Research that builds on fundamental scientific research to develop new therapies, medical procedures or diagnostics and advances it closer to the clinic.

Lab to clinic timeline: 5+ years
Clinical Studies
and Clinical Trials

Clinical research is the culmination of fundamental and translational research turning those research discoveries into treatments and interventions for people with MS.

Lab to clinic timeline: 1-5 years

Grant Awarded

  • Incubator Grant

Total Funding

  • $25,000

Duration

  • 1 year - starting 2020

Funding Partner

  • MS Angels
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search